Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-04T16:28:40.543Z Has data issue: false hasContentIssue false

29 - Cervical Cancer

from Section 5 - Gynecologic Oncology

Published online by Cambridge University Press:  01 February 2018

By
Jori S. Carter
Edited by
Lisa Keder  and
Martin E. Olsen
Lisa Keder
Affiliation:
Ohio State University
Martin E. Olsen
Affiliation:
East Tennessee State University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Gynecologic Care , pp. 279 - 289
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Cancer Society. Cervical cancer: what is cervical cancer? 2015. www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-key-statistics. (Accessed December 4, 2015.)Google Scholar
Bosch, FX, de Sanjose, S. Human papillomavirus and cervical cancer; burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31: 3–13.Google Scholar
Scheffner, M, Werness, BA, Huibregtse, JM et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63(6): 1129–36.CrossRefGoogle ScholarPubMed
Jones, RE, Wegrzyn, RJ, Patrick, DR et al. Identification of HPV-16 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein. J Biol Chem 1990; 154(22): 12782–5.Google Scholar
Castellsague, X, Munoz, N. Cofactors in human papillomavirus carcinogenesis: role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; 31: 20–8.Google Scholar
Louie, KS, Castellsaque, X, de Santiago, S et al. Smoking and passive smoking in cervical cancer risk: pooled analysis of couples from the IARC multicentric case-control studies. Cancer Epidemiol Biomarkers Prev 2011; 20(7): 1379–90.Google Scholar
McCann, MF, Irwin, DE, Walton, LA et al. Nicotine and cotinine in the cervical mucous of smokers, passive smokers, and nonsmokers. Cancer Epidemiol Biomarkers Prev 1992; 1(2): 125–9.Google Scholar
Smith, JS, Green, J, Berrington de Gonzalez, A et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361(9364): 1159–67.Google Scholar
Castle, PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis 2004; 8(3): 224–30.CrossRefGoogle ScholarPubMed
Lehtovirta, P, Finne, P, Nieminen, P et al. Prevalence and risk factors of squamous intraepithelial lesions of the cervix among HIV-infected women: a long-term follow-up study in a low-prevalence population. Int J STD AIDS 2006; 17(12): 831–4.Google Scholar
Anttila, T, Saikku, P, Koskela, P et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285(1): 47–51.Google Scholar
Nanda, K, McCrory, DC, Myers, ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132(10): 810–9.CrossRefGoogle ScholarPubMed
McCredie, MR, Sharples, KJ, Pual, C et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425–34.Google Scholar
Saslow, D, Solomon, D, Lawson, HW et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. ACS-ASCCO-ASCP Cervical Cancer Guideline Committee. CA Cancer J Clin 2012; 62: 147–72.CrossRefGoogle Scholar
Huh, WK, Ault, KA, Chelmow, D et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol 2015; 125: 330–7.Google Scholar
Petrosky, E, Bocchini, JA Jr, Hariri, S et al. Use of the 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2015; 64: 300–304.Google Scholar
Human papillomavirus vaccination. Committee Opinion No. 641. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015; 126: e38–43.Google Scholar
Centers for Disease Control. HPV vaccines: vaccinating your teen or preteen. www.cdc.gov/hpv/parents/vaccine.html. (Accessed February 17, 2016.)Google Scholar
Alfsen, GC, Kristensen, GB, Skovlund, E et al. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer 2001; 92(9): 2471–83.3.0.CO;2-K>CrossRefGoogle ScholarPubMed
Grigsby, PW, Perez, CA, Kuske, RR et al. Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother Oncol 1988; 12(4): 289–96.Google Scholar
Kilgore, LC, Soong, SJ, Gore, H et al. Analysis of prognostic features in adenocarcinoma of the cervix. Gynecol Oncol 1988; 31(1): 137–53.Google Scholar
Lee, KB, Lee, JM, Park, Cy et al. What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int J Gynecol Cancer 2006; 16(4): 1569–73.Google Scholar
Davy, ML, Dodd, TJ, Luke, CG et al. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003; 101(1): 38–45.Google Scholar
Eifel, PJ, Burke, TW, Morris, M et al. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995; 59(1): 38–44.Google Scholar
Eifel, PJ, Morris, M, Oswald, MJ et al. Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 cases. Cancer 1990; 65(11): 2507–14.Google Scholar
Hopkins, MP, Morley, GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991; 77(6): 912–7.Google ScholarPubMed
Lai, CH, Hsueh, S, Hong, JH et al. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery? Int J Gynecol Cancer 1999; 9(1): 28–36.Google Scholar
Lee, YY, Choi, CH, Kim, TJ et al. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol 2011; 120(3): 439–43.Google Scholar
Macdonald, OK, Chen, J, Dodson, M et al. Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix. Am J Clin Oncol 2009; 32(4): 411–6.CrossRefGoogle ScholarPubMed
Massad, LS, Einstein, MH, Huh, WK et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. 2012 ASCCP Consensus Guidelines Conference. J Low Genit Tract Dis 2013; 17: S1–27.Google Scholar
Quinn, MA, Benedet, JL, Odicino, F et al. Carcinoma of the cervix. FIGO 26th annual report on the results of treatment in gynecologic cancer. Int J Gynaecol Obstet 2006; 95 Suppl 1: S43.Google Scholar
Benedet, JL, Bender, H, Jones, H III et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70(2): 209–62.Google Scholar
Ostor, AG, Rome, RM. Micro-invasive squamous cell carcinoma of the cervix: a clinico-pathologic study of 200 cases with long-term follow-up. Int J Gynecol Cancer 1994; 4(4): 257–64.Google Scholar
Sedlis, A, Bundy, BN, Rotman, MZ et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with FIGO stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol 1999; 73(2): 177–83.Google Scholar
Peters, WA III, Liu, PY, Barrett, RJ II et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18(8): 1606–13.CrossRefGoogle ScholarPubMed
Milliken, DA, Shepherd, JH. Fertility preserving surgery for carcinoma of the cervix. Curr Opin Oncol 2008; 20(5): 575–80.Google Scholar
Landoni, F, Maneo, A, Colombo, A et al. Randomised study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet 1997; 350(9077): 535–40.CrossRefGoogle ScholarPubMed
Sutton, GP, Bundy, BN, Delgado, G et al. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166(1 Pt 1): 50–3.Google Scholar
Rose, PG, Bundy, BN, Watkins, EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144–53.Google Scholar
Whitney, CW, Sause, W, Bundy, BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17(5): 1339–48.CrossRefGoogle ScholarPubMed
Tewari, KS, Sill, MW, Long, HJ III et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370: 734–43.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×